Daniel Hartmann, Ujala Srivastava, Michaela Thaler, Karin N. Kleinhans, Gisèle N'Kontchou, Annika Scheffold, Kerstin Bauer, Ramona F. Kratzer, Natalia Kloos, Sarah‐Fee Katz, Zhangfa Song, Yvonne Begus‐Nahrmann, Alexander Kleger, Guido von Figura, Pavel Strnad, André Lechel, Cagatay Günes, Andrej Potthoff, Katja Deterding, Heiner Wedemeyer, Zhenyu Ju, Ge Song, Feng Xiao, Sonja Gillen, Hubert Schrezenmeier, Thomas Mertens, Marianne Ziol, Helmut Friess, Michael Jarek, Michael P. Manns, Michel Beaugrand, K.

Yong‐Ning Xin, Zhong‐Hua Lin, An‐Jin Chen, Shi‐Ying Xuan – 10 February 2011

Laura Lorenzon, Vincenzo Ziparo – 10 February 2011

Sandeep M. Patel, Seth Sweetser – 10 February 2011

Cristiano Quintini, Giuseppe D'Amico, Chase Brown, Federico Aucejo, Koji Hashimoto, Dympna M. Kelly, Bijan Eghtesad, Mark Sands, John J. Fung, Charles M. Miller – 4 February 2011 – Refractory ascites (RA) is a challenging complication after orthotopic liver transplantation. Its treatment consists of the removal of the precipitating factors. When the etiology is unknown, supportive treatment can be attempted. In severe cases, transjugular intrahepatic portosystemic shunts, portocaval shunts, and liver retransplantation have been used with marginal results.

Andrew King, Gail Masterton, Bridget Gunson, Simon Olliff, Doris Redhead, Kamarjit Mangat, Gabriel Oniscu, Peter Hayes, Dhiraj Tripathi – 4 February 2011 – The role of transjugular intrahepatic portosystemic shunt (TIPS) insertion in managing the complications of portal hypertension is well established, but its utility in patients who have previously undergone liver transplantation is not well documented. Twenty‐two orthotopic liver transplantation (OLT) patients and 44 nontransplant patients (matched controls) who underwent TIPS were analyzed.

Peter J. Lewindon, Grant A. Ramm – 31 January 2011

Liang Shen – 31 January 2011

Waka Ohishi, Saeko Fujiwara, John B. Cologne, Gen Suzuki, Masazumi Akahoshi, Nobuo Nishi, Masataka Tsuge, Kazuaki Chayama – 31 January 2011 – In cohort studies of atomic bomb survivors and Mayak nuclear facility workers, radiation‐associated increases in liver cancer risk were observed, but hepatitis B virus (HBV) and hepatitis C virus (HCV) infections were not taken strictly into account. We identified 359 hepatocellular carcinoma (HCC) cases between 1970 and 2002 in the cohort of atomic bomb survivors and estimated cumulative incidence of HCC by radiation dose.

Maria Stepanova, Zobair M. Younossi – 31 January 2011